[{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET09-01 DNA-reactive agents,,"},{"Key":"Keywords","Value":"Glioblastoma,Survival,Chemotherapy,MTL-004,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>M. Hudson<\/b><sup>1<\/sup>, S. Maubant<sup>2<\/sup>, E. Bertrand<sup>2<\/sup>, M. Lux<sup>2<\/sup>, J. Longin<sup>2<\/sup>, E. Marie Dit Chatel<sup>2<\/sup>, M. Ramelet<sup>2<\/sup>, O. Duchamp<sup>2<\/sup>; <br\/><sup>1<\/sup>Gordian Pharma Ltd., Pentre-bach, United Kingdom, <sup>2<\/sup>Oncodesign Services, Dijon, France","CSlideId":"","ControlKey":"8a114041-731b-4c38-afcf-fb62e13a7a88","ControlNumber":"10365","DisclosureBlock":"&nbsp;<b>M. Hudson, <\/b> None..<br><b>S. Maubant, <\/b> None..<br><b>E. Bertrand, <\/b> None..<br><b>M. Lux, <\/b> None..<br><b>J. Longin, <\/b> None..<br><b>E. Marie Dit Chatel, <\/b> None..<br><b>M. Ramelet, <\/b> None..<br><b>O. Duchamp, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10531","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"1","PosterboardNumber":"1","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB155","PresenterBiography":null,"PresenterDisplayName":"Mike Hudson, PhD","PresenterKey":"f37eb7a7-1ae3-4e7b-953e-71a23eed34cb","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB155. Intra-cranial administration of MTL-004, a promising post-resection treatment for glioblastoma","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"600","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Intra-cranial administration of MTL-004, a promising post-resection treatment for glioblastoma","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET09-02 Epigenetic targets,,"},{"Key":"Keywords","Value":"Epigenetics,Solid tumors,&#946;-catenin,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>E. Fisher<\/b><sup>1<\/sup>, A. Spinella<sup>1<\/sup>, J. Matsui<sup>2<\/sup>, K. Nomoto<sup>2<\/sup>, X. Varelas<sup>1<\/sup>, M. Bais<sup>3<\/sup>, M. Kukuruzinska<sup>3<\/sup>; <br\/><sup>1<\/sup>Boston University School of Medicine, Boston, MA, <sup>2<\/sup>Eisai Inc, Nutley, NJ, <sup>3<\/sup>Boston University School of Dental Medicine, Boston, MA","CSlideId":"","ControlKey":"cf0893e2-0292-4bab-b350-925efae4e96c","ControlNumber":"9943","DisclosureBlock":"&nbsp;<b>E. Fisher, <\/b> None..<br><b>A. Spinella, <\/b> None.&nbsp;<br><b>J. Matsui, <\/b> <br><b>Eisai Inc<\/b> Employment. <br><b>K. Nomoto, <\/b> <br><b>Eisai Inc<\/b> Employment.<br><b>X. Varelas, <\/b> None..<br><b>M. Bais, <\/b> None.&nbsp;<br><b>M. Kukuruzinska, <\/b> <br><b>Eisai Inc<\/b> Grant\/Contract.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10532","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"2","PosterboardNumber":"2","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB156","PresenterBiography":null,"PresenterDisplayName":"Emily Fisher, BA","PresenterKey":"cf4b0ee8-1507-45e5-95f9-6218092cd19c","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB156. Targeting epigenetic activity of beta-catenin\/CBP impedes oral cancer progression","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"600","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Targeting epigenetic activity of beta-catenin\/CBP impedes oral cancer progression","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET09-02 Epigenetic targets,,"},{"Key":"Keywords","Value":"Epigenetics,p300,Cancer therapy,c-Myc,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. Li<\/b>, Z. Tu, J. Peng, L. Fan, H. Yu, F. Wang, X. Li; <br\/>Hinova Pharmaceuticals, Chengdu Shi, China","CSlideId":"","ControlKey":"b824f4ef-9789-4b33-815c-83094933bc70","ControlNumber":"9834","DisclosureBlock":"&nbsp;<b>J. Li, <\/b> None..<br><b>Z. Tu, <\/b> None..<br><b>J. Peng, <\/b> None..<br><b>L. Fan, <\/b> None..<br><b>H. Yu, <\/b> None..<br><b>F. Wang, <\/b> None..<br><b>X. Li, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10533","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"3","PosterboardNumber":"3","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB157","PresenterBiography":null,"PresenterDisplayName":"Jing Li, PhD","PresenterKey":"e92cdb7c-4ffa-4cd4-8f32-1b41801efb92","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB157. Discovery of HP537, a potent and selective p300\/CBP inhibitor for the treatment of hematologic malignancies","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"600","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discovery of HP537, a potent and selective p300\/CBP inhibitor for the treatment of hematologic malignancies","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET09-02 Epigenetic targets,,"},{"Key":"Keywords","Value":"PARP inhibitors,Pancreatic cancer,HDAC inhibitor,Drug synergy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>A. M. Tsimberidou<\/b>, B. C. Valdez, B. Yuan, Y. Nieto, M. Baysal, A. Chakraborty, B. S. Andersson; <br\/>UT MD Anderson Cancer Center, Houston, TX","CSlideId":"","ControlKey":"42661ecc-4339-405c-9b1e-7d2a2ef2e451","ControlNumber":"10665","DisclosureBlock":"<b>&nbsp;A. M. Tsimberidou, <\/b> <br><b>Novocure<\/b> Grant\/Contract. <br><b>Agenus<\/b> Grant\/Contract. <br><b>Immatics<\/b> Grant\/Contract. <br><b>Tempus<\/b> Grant\/Contract. <br><b>OBI Pharma<\/b> Grant\/Contract. <br><b>Orionis<\/b> Grant\/Contract. <br><b>PICI<\/b> Grant\/Contract. <br><b>Tachyon<\/b> Grant\/Contract. <br><b>NEX-I<\/b> Independent Contractor. <br><b>Bryet<\/b> Independent Contractor. <br><b>Diaccurate<\/b> Independent Contractor. <br><b>Macrogenics<\/b> Independent Contractor. <br><b>VinceRx<\/b> Independent Contractor. <br><b>Avstera<\/b> Independent Contractor. <br><b>BIOECLIPLSE<\/b> Independent Contractor.<br><b>B. C. Valdez, <\/b> None..<br><b>B. Yuan, <\/b> None.&nbsp;<br><b>Y. Nieto, <\/b> <br><b>Secura Bio<\/b> Other, Research Support. <br><b>Novartis<\/b> Other, Research Support. <br><b>Astra Zeneca<\/b> Research Support. <br><b>Affimed<\/b> Other, Research Support.<br><b>M. Baysal, <\/b> None..<br><b>A. Chakraborty, <\/b> None.&nbsp;<br><b>B. S. Andersson, <\/b> <br><b>Race Oncology<\/b> Other, advisory role. <br><b>GreenJay Therapeutics<\/b> Other, advisory role.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10534","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"4","PosterboardNumber":"4","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB158","PresenterBiography":null,"PresenterDisplayName":"Apostolia Tsimberidou, MD;PhD","PresenterKey":"b3608c07-755c-404b-91a2-383b742f8dc2","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB158. Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in &#8203;pancreatic cancer cells: implications for novel therapy","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"600","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in &#8203;pancreatic cancer cells: implications for novel therapy","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET09-02 Epigenetic targets,,"},{"Key":"Keywords","Value":"BET inhibitor,Epigenetics,Cancer therapy,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. Li<\/b>, L. Fan, H. Yuan, Y. Huo, H. Yu, F. Wang, X. Li; <br\/>Hinova Pharmaceuticals, Chengdu Shi, China","CSlideId":"","ControlKey":"7fedc854-3b7c-4153-ae85-d0ef1b2f1089","ControlNumber":"9835","DisclosureBlock":"&nbsp;<b>J. Li, <\/b> None..<br><b>L. Fan, <\/b> None..<br><b>H. Yuan, <\/b> None..<br><b>Y. Huo, <\/b> None..<br><b>H. Yu, <\/b> None..<br><b>F. Wang, <\/b> None..<br><b>X. Li, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10535","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"5","PosterboardNumber":"5","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB159","PresenterBiography":null,"PresenterDisplayName":"Jing Li, PhD","PresenterKey":"e92cdb7c-4ffa-4cd4-8f32-1b41801efb92","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB159. Discovery of HP560, a novel BET inhibitor for the treatment of myelofibrosis","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"600","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discovery of HP560, a novel BET inhibitor for the treatment of myelofibrosis","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET09-03 HDAC and methyltransferase inhibitors,,"},{"Key":"Keywords","Value":"Decitabine,Mouse,Retrovirus,Interferons,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>S. Light<\/b>, M. Montazer, C. Wycoff, R. Tuttle, A. Brola, W. Wycoff, R. Johnson, Y. Liu; <br\/>Liberty University, Lynchburg, VA","CSlideId":"","ControlKey":"5d984aad-0e36-4887-9a1e-e44554d34fb8","ControlNumber":"10518","DisclosureBlock":"&nbsp;<b>S. Light, <\/b> None..<br><b>M. Montazer, <\/b> None..<br><b>C. Wycoff, <\/b> None..<br><b>R. Tuttle, <\/b> None..<br><b>A. Brola, <\/b> None..<br><b>W. Wycoff, <\/b> None..<br><b>R. Johnson, <\/b> None..<br><b>Y. Liu, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10536","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"6","PosterboardNumber":"6","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB160","PresenterBiography":null,"PresenterDisplayName":"Yingguang Liu, PhD","PresenterKey":"c88aba64-d1e8-4cd8-ba1a-7bcbe7ffcd54","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB160. The mouse mammary tumor virus mediates the antineoplastic action of decitabine","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"600","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"The mouse mammary tumor virus mediates the antineoplastic action of decitabine","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET09-04 Molecular glues,,"},{"Key":"Keywords","Value":"Prostate cancer,Kinase inhibitors,Drug resistance,Drug discovery,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>C. Lin<\/b>, Z. Li, K. Medley, D. J. Bearss, H. Vankayalapati; <br\/>Biolexis Therapeutics Inc., American Fork, UT","CSlideId":"","ControlKey":"5225a257-0108-4c25-8584-4e44ac5d3b57","ControlNumber":"10817","DisclosureBlock":"<b>&nbsp;C. Lin, <\/b> <br><b>Biolexis Therapeutics, Inc.<\/b> Employment. <br><b>Z. Li, <\/b> <br><b>Biolexis Therapeutics, Inc.<\/b> Employment. <br><b>K. Medley, <\/b> <br><b>Biolexis Therapeutics, Inc.<\/b> Employment, Stock Option. <br><b>D. J. Bearss, <\/b> <br><b>Biolexis Therapeutics, Inc.<\/b> Stock Option. <br><b>Signalexis<\/b> Stock Option. <br><b>Halia Therapeutics, Inc.<\/b> Employment, Stock Option. <br><b>University of Utah<\/b> Other, Scientific Advisor. <br><b>H. Vankayalapati, <\/b> <br><b>Biolexis Therapeutics, Inc.<\/b> Employment, Stock Option. <br><b>Signalexis<\/b> Employment, Stock Option. <br><b>Arrien Pharmaceuticals<\/b> Stock Option.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10537","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"7","PosterboardNumber":"7","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB161","PresenterBiography":null,"PresenterDisplayName":"Chenyu Li, PhD","PresenterKey":"39f7b1db-9aee-460e-af7e-da92c69eab05","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB161. Discovery of an oral, potent, and selective CDK9 molecular glue degrader SLX-3065 active in aggressive variant prostate cancers (AVPC)","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"600","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discovery of an oral, potent, and selective CDK9 molecular glue degrader SLX-3065 active in aggressive variant prostate cancers (AVPC)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET09-05 Novel antitumor agents,,"},{"Key":"Keywords","Value":"Fibroblast growth factor receptor (FGFR),Mutations,Solid tumors,Tinengotinib,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>S. Piha-Paul<\/b><sup>1<\/sup>, C.-Y. Liao<sup>2<\/sup>, L. Fonkoua<sup>3<\/sup>, A. MahipaI<sup>4<\/sup>, S. Goel<sup>5<\/sup>, C. Fountzilas<sup>6<\/sup>, L. Shen<sup>7<\/sup>, D. Li<sup>8<\/sup>, D. Deming<sup>9<\/sup>, F. Dayyani<sup>10<\/sup>, W. Han<sup>11<\/sup>, Z. Niu<sup>12<\/sup>, J. Fan<sup>13<\/sup>, P. Peng<sup>14<\/sup>, H. Wang<sup>14<\/sup>, P. Huang<sup>14<\/sup>, F. Wu<sup>14<\/sup>, M. Javle<sup>1<\/sup>; <br\/><sup>1<\/sup>University of Texas MD Anderson Cancer Center, Houston, TX, <sup>2<\/sup>The University of Chicago Medicine and Biological Sciences, Chicago, IL, <sup>3<\/sup>Mayo Clinic in Rochester, Rochester, MN, <sup>4<\/sup>University Hospitals Cleveland Medical Center, Cleveland, OH, <sup>5<\/sup>Rutgers Cancer Center Institute of New Jersey, New Jersey, NJ, <sup>6<\/sup>Roswell Park Comprehensive Cancer Center, Buffalo, NY, <sup>7<\/sup>Beijing Cancer Hospital, Beijing, China, <sup>8<\/sup>City of Hope National Medical Center, Duarte, CA, <sup>9<\/sup>University of Wisconsin Carbone Cancer Center, Madison, WI, <sup>10<\/sup>University of California, Irvine, Irvine, CA, <sup>11<\/sup>Hunan Cancer Hospital, Changsha, China, <sup>12<\/sup>Shandong Cancer Hospital, Jinan, China, <sup>13<\/sup>TransThera Sciences (US), Inc., Gaithersburg, MD, <sup>14<\/sup>TransThera  Sciences (Nanjing), Inc., Nanjing, China","CSlideId":"","ControlKey":"a93bff0e-e691-4488-88eb-bd28ba182947","ControlNumber":"10502","DisclosureBlock":"<b>&nbsp;S. Piha-Paul, <\/b> <br><b>Abbvie; Aminex; Biomarin; Boehringer Ingelheim; Bristol-Myers Squibb; Cerulean Pharma; Chugai Pharma; Curis; Five Prime Therapeutics; Genmab; GlaxoSmithKline; Helix BioPharma; Incyte; Jacobio<\/b> Grant\/Contract. <br><b>MedImmune; Medivation; Merck Sharp & Dohme; Novartis; Pieris Pharmaceuticals; Pfizer; Principa Biopharma; Puma Biotechnology; RAPT Therapeutics; Seagen; Taiho Oncology; Tesaro; TransThera Sciences<\/b> Grant\/Contract. <br><b>Amphivena Therapeutics; Alkermes; Daiichi Sankyo; Lilly; ABM; Acepodia; ENB Therapeutics; Gene Quantum; Silverback Therapeutics; Cyclacel; F-Star; HiberCell; Immunomedics; Lytix Biopharma<\/b> Grant\/Contract. <br><b>Gilead Sciences; Phanes Therapeutics; Purinomia; ZielBio; Hengrui Pharmaceutical; Replimune; Synlogic; Epigenetix; Immorna; Jiangsu Simcere Pharmaceutical Co. Ltd.; Nectin Therapeutics<\/b> Grant\/Contract. <br><b>C. Liao, <\/b> <br><b>Astrazeneca<\/b> Travel, Other, Consulting, speaking. <br><b>Incyte<\/b> Travel, Other, Consulting, speeaking. <br><b>Ipsen<\/b> Other, Consulting. <br><b>Transthera<\/b> Other, Consulting. <br><b>Eli Lilly<\/b> Other, Consulting. <br><b>Lantheus<\/b> Other, Consulting\u000d\u000a. <br><b>Boston Scientific<\/b> Travel, Other, Consulting.<br><b>L. Fonkoua, <\/b> None..<br><b>A. MahipaI, <\/b> None..<br><b>S. Goel, <\/b> None.&nbsp;<br><b>C. Fountzilas, <\/b> <br><b>Merck; Lilly; Astellas Pharma; Rafael Pharmaceuticals; Pfizer; Seagen; Corcept Therapeutics;  Ipsen; ERYTECH Pharma; Taiho Oncology; Kadmon; Dragonfly Therapeutics; Aravive<\/b> Research Funding. <br><b>Bristol-Myers Squibb\/Ono Pharmaceutical; TransThera Biosciences; CrystalGenomics; Bellicum Pharmaceuticals; AstraZeneca; Biomea Fusion; Amgen; Valar Labs; Sanofi<\/b> Research Funding. <br><b>CG Pharmaceuticals<\/b> Other, Travel, Accommodations, Expenses.<br><b>L. Shen, <\/b> None.&nbsp;<br><b>D. Li, <\/b> <br><b>AbbVie; Adagene; AstraZeneca; Delcath; Eisai; Exelixis; Genentech; Ipsen Biopharmaceuticals; Merck; Sumitomo; TriSalus<\/b> Independent Contractor, Other, Consultant. <br><b>AstraZeneca<\/b> Grant\/Contract. <br><b>Brooklyn ImmunoTherapeutics<\/b> Grant\/Contract.<br><b>D. Deming, <\/b> None.&nbsp;<br><b>F. Dayyani, <\/b> <br><b>Takeda, Sirtex, Servier, Ipsen, Exelixis, Astellas<\/b> Other, Speakers Bureau. <br><b>Sirtex, Exelixis, Eisai, Astrazeneca<\/b> Other, Consulting.<br><b>W. Han, <\/b> None..<br><b>Z. Niu, <\/b> None.&nbsp;<br><b>J. Fan, <\/b> <br><b>TransThera<\/b> Employment. <br><b>P. Peng, <\/b> <br><b>TransThera<\/b> Employment. <br><b>H. Wang, <\/b> <br><b>TransThera<\/b> Employment. <br><b>P. Huang, <\/b> <br><b>TransThera<\/b> Employment. <br><b>F. Wu, <\/b> <br><b>TransThera<\/b> Employment.<br><b>M. Javle, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10538","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"8","PosterboardNumber":"8","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB162","PresenterBiography":null,"PresenterDisplayName":"Peng Huang, M Pharm","PresenterKey":"3885a355-119f-446b-951c-f41d252a78e2","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB162. Tinengotinib in patients with advanced solid tumors harboring actionable FGFR1-3 mutations","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"600","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Tinengotinib in patients with advanced solid tumors harboring actionable FGFR1-3 mutations","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET09-05 Novel antitumor agents,,"},{"Key":"Keywords","Value":"KRAS,Cancer,Colon cancer,Pancreatic cancer,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Y. W. Zhang<\/b><sup>1<\/sup>, E. D. Vo<sup>2<\/sup>, P. Gan<sup>1<\/sup>, D. Rominger<sup>1<\/sup>, J. M. Silva<sup>2<\/sup>, Y. J. Zhang<sup>1<\/sup>, C. Pan<sup>1<\/sup>, G. Lee<sup>2<\/sup>, J. M. Micozzi<sup>1<\/sup>, B. Reid<sup>2<\/sup>, B. McDonough<sup>2<\/sup>, A. Sinha<sup>2<\/sup>, A. Hospital<sup>1<\/sup>, D. Krauth<sup>1<\/sup>, J. I. Luengo<sup>1<\/sup>, M. Kramer<sup>1<\/sup>, C. Pitt<sup>2<\/sup>, H. Lin<sup>1<\/sup>; <br\/><sup>1<\/sup>Quanta Therapeutics, Radnor, PA, <sup>2<\/sup>Quanta Therapeutics, South San Francisco, CA","CSlideId":"","ControlKey":"df1627ea-cb91-484d-a751-12a1321000da","ControlNumber":"10776","DisclosureBlock":"<b>&nbsp;Y. W. Zhang, <\/b> <br><b>Quanta Therapeutics<\/b> Employment, Stock Option. <br><b>E. D. Vo, <\/b> <br><b>Quanta Therapeutics<\/b> Employment, Stock Option. <br><b>P. Gan, <\/b> <br><b>Quanta Therapeutics<\/b> Employment, Stock Option. <br><b>Incyte Corporation<\/b> Employment, Stock Option. <br><b>D. Rominger, <\/b> <br><b>Quanta Therapeutics<\/b> Employment, Stock Option. <br><b>J. M. Silva, <\/b> <br><b>Quanta Therapeutics<\/b> Employment, Stock Option. <br><b>Y. J. Zhang, <\/b> <br><b>Quanta Therapeutics<\/b> Employment, Stock Option. <br><b>C. Pan, <\/b> <br><b>Quanta Therapeutics<\/b> Employment, Stock Option. <br><b>G. Lee, <\/b> <br><b>Quanta Therapeutics<\/b> Employment, Stock Option. <br><b>J. M. Micozzi, <\/b> <br><b>Quanta Therapeutics<\/b> Employment, Stock Option. <br><b>B. Reid, <\/b> <br><b>Quanta Therapeutics<\/b> Employment, Stock Option. <br><b>B. McDonough, <\/b> <br><b>Quanta Therapeutics<\/b> Employment, Stock Option. <br><b>A. Sinha, <\/b> <br><b>Quanta Therapeutics<\/b> Employment, Stock Option. <br><b>A. Hospital, <\/b> <br><b>Quanta Therapeutics<\/b> Employment, Stock Option. <br><b>D. Krauth, <\/b> <br><b>Quanta Therapeutics<\/b> Employment, Stock Option. <br><b>J. I. Luengo, <\/b> <br><b>Quanta Therapeutics<\/b> Employment, Stock Option. <br><b>M. Kramer, <\/b> <br><b>Quanta Therapeutics<\/b> Employment, Stock Option. <br><b>Trevena, Inc<\/b> Employment, Stock Option. <br><b>C. Pitt, <\/b> <br><b>Quanta Therapeutics<\/b> Employment, Stock Option. <br><b>H. Lin, <\/b> <br><b>Quanta Therapeutics<\/b> Employment, Stock Option.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10539","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"9","PosterboardNumber":"9","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB163","PresenterBiography":null,"PresenterDisplayName":"Yang Zhang, PhD","PresenterKey":"4a11fc9b-16bb-49b9-9852-20c11a8e4a5b","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB163. Discovery and characterization of QTX3544, a potent, selective, and orally bioavailable allosteric G12V preferring multi KRAS inhibitor","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"600","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discovery and characterization of QTX3544, a potent, selective, and orally bioavailable allosteric G12V preferring multi KRAS inhibitor","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET09-05 Novel antitumor agents,,"},{"Key":"Keywords","Value":"Cancer,,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>T. J. Read<\/b>, R. Steel, A. Golialei, J. Rimel, L. Damon, J. Azofeifa; <br\/>Arpeggio Biosciences, Boulder, CO","CSlideId":"","ControlKey":"bad081e4-f304-4561-8436-d7dc56473fa4","ControlNumber":"9842","DisclosureBlock":"&nbsp;<b>T. J. Read, <\/b> None..<br><b>R. Steel, <\/b> None..<br><b>A. Golialei, <\/b> None..<br><b>J. Rimel, <\/b> None..<br><b>L. Damon, <\/b> None..<br><b>J. Azofeifa, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10540","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"10","PosterboardNumber":"10","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB164","PresenterBiography":null,"PresenterDisplayName":"Timothy Read, PhD","PresenterKey":"764ce31b-9a51-4806-a9a4-904fb99513ac","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB164. Inducing immunogenic cell death in difficult-to-treat cancers with an orally-bioavailable GPX4 inhibitor","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"600","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Inducing immunogenic cell death in difficult-to-treat cancers with an orally-bioavailable GPX4 inhibitor","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET09-05 Novel antitumor agents,,"},{"Key":"Keywords","Value":"KRAS,cyclophilin A,GFH547,Cancer,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"F. Yan, J. Zhao, T. Liang, T. Jiang, C. Lin, L. Peng, K. Ma, H. Yang, W. He, Z. Li, L. Zhang, X. Xu, Y. Zhao, X. Zhang, Y. Ni, Q. Liu, J. Gao, F. Xie, X. Gao, X. Lan, L. Wang, J. Zhang, H. Ren, D. Liu, S. Le, <b>F. Zhou<\/b>, J. Lan, Q. Lu; <br\/>GenFleet Therapeutics, Shanghai, China","CSlideId":"","ControlKey":"e4233cb9-52c0-4e1c-a258-e62af73e2863","ControlNumber":"10499","DisclosureBlock":"<b>&nbsp;F. Yan, <\/b> <br><b>GenFleet Therapeutics<\/b> Employment. <br><b>J. Zhao, <\/b> <br><b>GenFleet Therapeutics<\/b> Employment. <br><b>T. Liang, <\/b> <br><b>GenFleet Therapeutics<\/b> Employment. <br><b>T. Jiang, <\/b> <br><b>GenFleet Therapeutics<\/b> Employment. <br><b>C. Lin, <\/b> <br><b>GenFleet Therapeutics<\/b> Employment. <br><b>L. Peng, <\/b> <br><b>GenFleet Therapeutics<\/b> Employment. <br><b>K. Ma, <\/b> <br><b>GenFleet Therapeutics<\/b> Employment. <br><b>H. Yang, <\/b> <br><b>GenFleet Therapeutics<\/b> Employment. <br><b>W. He, <\/b> <br><b>GenFleet Therapeutics<\/b> Employment. <br><b>Z. Li, <\/b> <br><b>GenFleet Therapeutics<\/b> Employment. <br><b>L. Zhang, <\/b> <br><b>GenFleet Therapeutics<\/b> Employment. <br><b>X. Xu, <\/b> <br><b>GenFleet Therapeutics<\/b> Employment. <br><b>Y. Zhao, <\/b> <br><b>GenFleet Therapeutics<\/b> Employment. <br><b>X. Zhang, <\/b> <br><b>GenFleet Therapeutics<\/b> Employment. <br><b>Y. Ni, <\/b> <br><b>GenFleet Therapeutics<\/b> Employment. <br><b>Q. Liu, <\/b> <br><b>GenFleet Therapeutics<\/b> Employment. <br><b>J. Gao, <\/b> <br><b>GenFleet Therapeutics<\/b> Employment. <br><b>F. Xie, <\/b> <br><b>GenFleet Therapeutics<\/b> Employment. <br><b>X. Gao, <\/b> <br><b>GenFleet Therapeutics<\/b> Employment. <br><b>X. Lan, <\/b> <br><b>GenFleet Therapeutics<\/b> Employment. <br><b>L. Wang, <\/b> <br><b>GenFleet Therapeutics<\/b> Employment. <br><b>J. Zhang, <\/b> <br><b>GenFleet Therapeutics<\/b> Employment. <br><b>H. Ren, <\/b> <br><b>GenFleet Therapeutics<\/b> Employment. <br><b>D. Liu, <\/b> <br><b>GenFleet Therapeutics<\/b> Employment. <br><b>S. Le, <\/b> <br><b>GenFleet Therapeutics<\/b> Employment. <br><b>F. Zhou, <\/b> <br><b>GenFleet Therapeutics<\/b> Employment. <br><b>J. Lan, <\/b> <br><b>GenFleet Therapeutics<\/b> Employment. <br><b>Q. Lu, <\/b> <br><b>GenFleet Therapeutics<\/b> Employment.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10541","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"11","PosterboardNumber":"11","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB165","PresenterBiography":null,"PresenterDisplayName":"Fusheng Zhou, PhD","PresenterKey":"11ab1020-7c88-4343-a7da-17bb65eea252","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB165. GFH547: An orally bioavailable, cyclophilin A-hijacking panRAS(on) inhibitor with broad spectrum anti-tumor activities","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"600","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"GFH547: An orally bioavailable, cyclophilin A-hijacking panRAS(on) inhibitor with broad spectrum anti-tumor activities","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET09-05 Novel antitumor agents,,"},{"Key":"Keywords","Value":"Adenosine,Antitumor agents,Immune checkpoint blockade,Tumor microenvironment,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"S. Han, N. Kim, H. He, <b>Z. Chu<\/b>; <br\/>Crossignal Therapeutics, Inc, La Jolla, CA","CSlideId":"","ControlKey":"13dfc434-143c-4bb9-9500-9d867ccbcdab","ControlNumber":"10770","DisclosureBlock":"<b>&nbsp;S. Han, <\/b> <br><b>Crossignal Therapeutics<\/b> Employment. <br><b>N. Kim, <\/b> <br><b>Crossignal Therapeutics<\/b> Employment. <br><b>H. He, <\/b> <br><b>Crossignal Therapeutics<\/b> Employment. <br><b>Z. Chu, <\/b> <br><b>Crossignal Therapeutics<\/b> Employment.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10542","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"12","PosterboardNumber":"12","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB166","PresenterBiography":null,"PresenterDisplayName":"Zhi-Liang (Zak) Chu, PhD","PresenterKey":"994ff553-196c-4e44-9bb2-3bd4e91b5d82","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB166. Discovery of CT3021, a novel potent adenosine A2a\/A2b\/A1 receptor triple antagonist","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"600","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discovery of CT3021, a novel potent adenosine A2a\/A2b\/A1 receptor triple antagonist","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET09-05 Novel antitumor agents,,"},{"Key":"Keywords","Value":"Breast cancer,Target discovery,Mesenchymal-epithelial transition (MET),,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"M. Mizunuma, C. Redon, L. Saha, N. Takebe, <b>Y. G. Pommier<\/b>; <br\/>National Cancer Institute, Bethesda, MD","CSlideId":"","ControlKey":"108fc320-7391-4e4f-a6ee-91ce2c181f96","ControlNumber":"10416","DisclosureBlock":"&nbsp;<b>M. Mizunuma, <\/b> None..<br><b>C. Redon, <\/b> None..<br><b>L. Saha, <\/b> None..<br><b>N. Takebe, <\/b> None..<br><b>Y. G. Pommier, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10543","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"13","PosterboardNumber":"13","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB167","PresenterBiography":null,"PresenterDisplayName":"Yves Pommier, MD;PhD","PresenterKey":"7419b4a6-a638-4384-8091-249758dc386a","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB167. Acetalax (Oxyphenisatin acetate, NSC 59687) and bisacodyl (dulcolax) cause oncosis in triple negative breast cancer by poisoning the ion exchange membrane protein TRPM4","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"600","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Acetalax (Oxyphenisatin acetate, NSC 59687) and bisacodyl (dulcolax) cause oncosis in triple negative breast cancer by poisoning the ion exchange membrane protein TRPM4","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET09-05 Novel antitumor agents,,"},{"Key":"Keywords","Value":"CDK7,CDK inhibitor,Cell cycle,Transcriptional regulation,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>H. Park<\/b>, K. Seo, J. Yu, J. Kim, M. Joo, S. Kim, J. Lee, J. Lee, E.-J. Kim, J. Nam, W. Han; <br\/>Cyrus Therapeutics, Seoul, Korea, Republic of","CSlideId":"","ControlKey":"1b45a2f2-c6ea-4ba7-a75f-6c092e53e533","ControlNumber":"10881","DisclosureBlock":"<b>&nbsp;H. Park, <\/b> <br><b>Cyrus Therapeutics<\/b> Employment. <br><b>K. Seo, <\/b> <br><b>Cyrus Therapeutics<\/b> Employment. <br><b>J. Yu, <\/b> <br><b>Cyrus Therapeutics<\/b> Employment. <br><b>J. Kim, <\/b> <br><b>Cyrus Therapeutics<\/b> Employment. <br><b>M. Joo, <\/b> <br><b>Cyrus Therapeutics<\/b> Employment. <br><b>S. Kim, <\/b> <br><b>Cyrus Therapeutics<\/b> Employment. <br><b>J. Lee, <\/b> <br><b>Cyrus Therapeutics<\/b> Employment. <br><b>J. Lee, <\/b> <br><b>Cyrus Therapeutics<\/b> Employment. <br><b>E. Kim, <\/b> <br><b>Cyrus Therapeutics<\/b> Employment. <br><b>J. Nam, <\/b> <br><b>Cyrus Therapeutics<\/b> Employment. <br><b>W. Han, <\/b> <br><b>Cyrus Therapeutics<\/b> Employment.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10544","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"14","PosterboardNumber":"14","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB168","PresenterBiography":null,"PresenterDisplayName":"Heuijoon Park, PhD","PresenterKey":"1ad62d9b-c67a-4004-9444-85ab32efe2b7","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB168. A selective, potent, and orally bioavailable CDK7 inhibitor demonstrates superior anti-cancer activity in colorectal cancer models","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"600","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A selective, potent, and orally bioavailable CDK7 inhibitor demonstrates superior anti-cancer activity in colorectal cancer models","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET09-05 Novel antitumor agents,,"},{"Key":"Keywords","Value":"Cancer,,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>T. J. Read<\/b>, L. Damon, R. Yoo, C. Grochala, C. Liechty, C. Rhine, J. Rimel, D. Simpson, R. Lundblad, C. Pham, R. Steel, J. Azofeifa; <br\/>Arpeggio Biosciences, Boulder, CO","CSlideId":"","ControlKey":"976c7073-5b73-4092-abf4-a75659343aed","ControlNumber":"9843","DisclosureBlock":"&nbsp;<b>T. J. Read, <\/b> None..<br><b>L. Damon, <\/b> None..<br><b>R. Yoo, <\/b> None..<br><b>C. Grochala, <\/b> None..<br><b>C. Liechty, <\/b> None..<br><b>C. Rhine, <\/b> None..<br><b>J. Rimel, <\/b> None..<br><b>D. Simpson, <\/b> None..<br><b>R. Lundblad, <\/b> None..<br><b>C. Pham, <\/b> None..<br><b>R. Steel, <\/b> None..<br><b>J. Azofeifa, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10545","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"15","PosterboardNumber":"15","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB169","PresenterBiography":null,"PresenterDisplayName":"Timothy Read, PhD","PresenterKey":"764ce31b-9a51-4806-a9a4-904fb99513ac","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB169. Using a global reporter on transcript abundance to identify a selective inhibitor of Nrf2 signaling in KEAP1-mutant non small cell lung cancer","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"600","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Using a global reporter on transcript abundance to identify a selective inhibitor of Nrf2 signaling in KEAP1-mutant non small cell lung cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET09-05 Novel antitumor agents,,"},{"Key":"Keywords","Value":"Prodrugs,Cancer therapy,Drug design,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>M. Lu<\/b><sup>1<\/sup>, Y. Xing<sup>1<\/sup>, K.-J. Lee<sup>1<\/sup>, X. Ren<sup>1<\/sup>, J. R. Pritchard<sup>2<\/sup>, B. C. Cheng<sup>1<\/sup>, H. He<sup>3<\/sup>, S. Zheng<sup>1<\/sup>; <br\/><sup>1<\/sup>Carnegie Mellon University, Pittsburgh, PA, <sup>2<\/sup>Pennsylvania State University, State College, PA, <sup>3<\/sup>Captis Diagnostics, Pittsburgh, PA","CSlideId":"","ControlKey":"6e21cf2d-73a5-45aa-a9fb-073fb8e70fc2","ControlNumber":"10720","DisclosureBlock":"&nbsp;<b>M. Lu, <\/b> None..<br><b>Y. Xing, <\/b> None..<br><b>K. Lee, <\/b> None..<br><b>X. Ren, <\/b> None..<br><b>J. R. Pritchard, <\/b> None..<br><b>B. C. Cheng, <\/b> None.&nbsp;<br><b>H. He, <\/b> <br><b>Captis Diagnostics, LLC<\/b> Employment.<br><b>S. Zheng, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10546","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"16","PosterboardNumber":"16","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB170","PresenterBiography":null,"PresenterDisplayName":"Mengrou Lu, MS","PresenterKey":"0aaa4045-e0aa-4b43-8ef2-a284c8bd744b","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB170. AND-gate dual-targeting EGFR and PD-L1 with a split prodrug converter enzyme for cancer treatment","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"600","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"AND-gate dual-targeting EGFR and PD-L1 with a split prodrug converter enzyme for cancer treatment","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET09-06 Novel targets and pathways,,"},{"Key":"Keywords","Value":"Small molecule inhibitor,RNA methylation,METTL1,Translation,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>A. Sapetschnig<\/b><sup>1<\/sup>, B. Thomas<sup>1<\/sup>, E. Yankova<sup>2<\/sup>, H. Fischl<sup>1<\/sup>, A. Azevedo<sup>1<\/sup>, S. Bucknell<sup>1<\/sup>, R. Fosbeary<sup>1<\/sup>, S. Sawyer<sup>1<\/sup>, S. Evans<sup>2<\/sup>, C. Livi<sup>1<\/sup>, B. Andrews<sup>1<\/sup>, J. Rogan<sup>1<\/sup>, N. Webster<sup>1<\/sup>, M. Fyfe<sup>1<\/sup>, K. Tzelepis<sup>2<\/sup>, O. Rausch<sup>1<\/sup>; <br\/><sup>1<\/sup>Storm Therapeutics, Cambridge, United Kingdom, <sup>2<\/sup>Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom","CSlideId":"","ControlKey":"8681c817-50ec-425f-bc24-2d1d7e0ed984","ControlNumber":"10676","DisclosureBlock":"<b>&nbsp;A. Sapetschnig, <\/b> <br><b>Storm Therapeutics Ltd<\/b> Employment. <br><b>B. Thomas, <\/b> <br><b>Storm Therapeutics Ltd<\/b> Employment. <br><b>E. Yankova, <\/b> <br><b>Storm Therapeutics Ltd<\/b> Grant\/Contract. <br><b>H. Fischl, <\/b> <br><b>Storm Therapeutics Ltd<\/b> Employment. <br><b>A. Azevedo, <\/b> <br><b>Storm Therapeutics Ltd<\/b> Employment. <br><b>S. Bucknell, <\/b> <br><b>Storm Therapeutics Ltd<\/b> Employment. <br><b>R. Fosbeary, <\/b> <br><b>Storm Therapeutics Ltd<\/b> Employment. <br><b>S. Sawyer, <\/b> <br><b>Storm Therapeutics Ltd<\/b> Employment. <br><b>S. Evans, <\/b> <br><b>Storm Therapeutics Ltd<\/b> Grant\/Contract. <br><b>C. Livi, <\/b> <br><b>Storm Therapeutics Ltd<\/b> Employment. <br><b>B. Andrews, <\/b> <br><b>Storm Therapeutics Ltd<\/b> Employment. <br><b>J. Rogan, <\/b> <br><b>Storm Therapeutics Ltd<\/b> Employment. <br><b>N. Webster, <\/b> <br><b>Storm Therapeutics Ltd<\/b> Employment. <br><b>M. Fyfe, <\/b> <br><b>Storm Therapeutics Ltd<\/b> Employment. <br><b>K. Tzelepis, <\/b> <br><b>Storm Therapeutics Ltd<\/b> Grant\/Contract. <br><b>Wellcome<\/b> Grant\/Contract. <br><b>O. Rausch, <\/b> <br><b>Storm Therapeutics Ltd<\/b> Employment.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10547","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"17","PosterboardNumber":"17","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB171","PresenterBiography":null,"PresenterDisplayName":"Alexandra Sapetschnig, DrRerNat","PresenterKey":"341e6f9f-076c-4a0c-988c-18bfecbb1b12","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB171. First-in-class inhibitors of the tRNA methyltransferase METTL1 for the treatment of cancer","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"600","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"First-in-class inhibitors of the tRNA methyltransferase METTL1 for the treatment of cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET09-06 Novel targets and pathways,,"},{"Key":"Keywords","Value":"Cholangiocarcinoma,Serine\/threonine kinase,Small molecule drugs,Signal transduction pathways,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>P. P. Desai<\/b><sup>1<\/sup>, T. M. Khan<sup>2<\/sup>, R. I. Ayabe<sup>3<\/sup>, E. Smith<sup>1<\/sup>, S. Sinha<sup>1<\/sup>, A. Rainey<sup>1<\/sup>, Y. Lin<sup>1<\/sup>, T. Pu<sup>1<\/sup>, K. Lubrice<sup>1<\/sup>, L. Sarvestani<sup>1<\/sup>, S. Akmal<sup>4<\/sup>, S. Rehman<sup>5<\/sup>, K. Remmert<sup>1<\/sup>, M. Yaffe<sup>6<\/sup>, C. Thomas<sup>7<\/sup>, J. Brognard<sup>8<\/sup>, J. M. Hernandez<sup>1<\/sup>; <br\/><sup>1<\/sup>National Institutes of Health, Bethesda, MD, <sup>2<\/sup>Icahn School of Medicine at Mount Sinai, New york, NY, <sup>3<\/sup>MD Anderson Cancer Center, Houston, TX, <sup>4<\/sup>Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, <sup>5<\/sup>Yale School of Medicine, New Haven, CT, <sup>6<\/sup>Massachusetts Institute of Technology, Cambridge, MA, <sup>7<\/sup>National Institutes of Health, Rockville, MD, <sup>8<\/sup>National Institutes of Health, Fredrick, MD","CSlideId":"","ControlKey":"1871e475-2373-4476-8818-a04db5ad2c9d","ControlNumber":"10874","DisclosureBlock":"&nbsp;<b>P. P. Desai, <\/b> None..<br><b>T. M. Khan, <\/b> None..<br><b>R. I. Ayabe, <\/b> None..<br><b>E. Smith, <\/b> None..<br><b>S. Sinha, <\/b> None..<br><b>A. Rainey, <\/b> None..<br><b>Y. Lin, <\/b> None..<br><b>T. Pu, <\/b> None..<br><b>K. Lubrice, <\/b> None..<br><b>L. Sarvestani, <\/b> None..<br><b>S. Akmal, <\/b> None..<br><b>S. Rehman, <\/b> None..<br><b>K. Remmert, <\/b> None..<br><b>M. Yaffe, <\/b> None..<br><b>C. Thomas, <\/b> None..<br><b>J. Brognard, <\/b> None.&nbsp;<br><b>J. M. Hernandez, <\/b> <br><b>Aveo Oncology<\/b> Grant\/Contract.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10548","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"18","PosterboardNumber":"18","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB172","PresenterBiography":null,"PresenterDisplayName":"Priyanka Prakash Desai, PhD,MS,BS","PresenterKey":"14d5a267-4fd2-4853-a073-2d9e74703cf5","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB172. A cytosolic complex between exportin-7(XPO7) and ste20-like kinase (SLK) regulates PI3K-AKT-mTOR signaling in cholangiocarcinoma","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"600","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A cytosolic complex between exportin-7(XPO7) and ste20-like kinase (SLK) regulates PI3K-AKT-mTOR signaling in cholangiocarcinoma","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET09-07 PI3K\/AKT inhibitors,,"},{"Key":"Keywords","Value":"Akt,Breast cancer,Endometrial cancer,Precision medicine,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>E. A. Murphy<\/b>, M. D. Bartberger, M. Ibanez, T. T. Smith, N. Alvarez, N. Timple, X. Zhu, K. Fan, K. Yu; <br\/>Alterome Therapeutics Inc, San Diego, CA","CSlideId":"","ControlKey":"9f7a8438-4eb1-4275-b5b0-5293a41672b3","ControlNumber":"10548","DisclosureBlock":"<b>&nbsp;E. A. Murphy, <\/b> <br><b>Alterome Therapeutics<\/b> Employment, Fiduciary Officer, Stock Option. <br><b>M. D. Bartberger, <\/b> <br><b>Alterome Therapeutics<\/b> Employment, Stock, Stock Option, Patent. <br><b>M. Ibanez, <\/b> <br><b>Alterome Therapeutics<\/b> Employment, Stock Option. <br><b>Biosplice Therapeutics<\/b> Employment, Patent. <br><b>T. T. Smith, <\/b> <br><b>Alterome Therapeutics<\/b> Employment, Stock Option. <br><b>N. Alvarez, <\/b> <br><b>Alterome Therapeutics<\/b> Employment, Stock Option. <br><b>N. Timple, <\/b> <br><b>Alterome Therapeutics<\/b> Employment, Stock Option. <br><b>Kinnate Biopharma<\/b> Employment, Stock. <br><b>X. Zhu, <\/b> <br><b>Alterome Therapeutics<\/b> Employment, Stock Option. <br><b>K. Fan, <\/b> <br><b>Alterome Therapeutics<\/b> Employment, Stock Option. <br><b>K. Yu, <\/b> <br><b>Alterome Therapeutics<\/b> Employment, Stock Option.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10549","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"19","PosterboardNumber":"19","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB173","PresenterBiography":null,"PresenterDisplayName":"ERIC MURPHY","PresenterKey":"a57c3fa9-517f-4e3a-902f-0c51c3bf58bd","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB173. Discovery of ALTA-2618, the first allosteric, mutant-selective targeted therapy for AKT1 E17K driven cancers","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"600","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discovery of ALTA-2618, the first allosteric, mutant-selective targeted therapy for AKT1 E17K driven cancers","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET09-07 PI3K\/AKT inhibitors,,"},{"Key":"Keywords","Value":"PI3K,Brain tumors,Pharmacokinetics,Blood-brain barrier,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>A. A. Strait<\/b>, M. A. Taylor, K. S. Litwiler, Q. Zhao, D. A. Mareska, M. L. Boys, Y. Izrayelit, R. Woessner, J. D. Winkler; <br\/>Onkure, Inc., Boulder, CO","CSlideId":"","ControlKey":"88348167-5fa7-417e-8b17-6d4372deceb7","ControlNumber":"10324","DisclosureBlock":"<b>&nbsp;A. A. Strait, <\/b> <br><b>Onkure, Inc.<\/b> Employment, Stock Option. <br><b>M. A. Taylor, <\/b> <br><b>Onkure, Inc.<\/b> Employment, Stock Option. <br><b>K. S. Litwiler, <\/b> <br><b>Onkure, Inc.<\/b> Employment, Stock Option. <br><b>Q. Zhao, <\/b> <br><b>Onkure, Inc.<\/b> Employment, Stock Option. <br><b>D. A. Mareska, <\/b> <br><b>Onkure, Inc.<\/b> Employment, Stock Option. <br><b>M. L. Boys, <\/b> <br><b>Onkure, Inc.<\/b> Employment, Stock Option. <br><b>Pfizer, Inc<\/b> Stock. <br><b>Y. Izrayelit, <\/b> <br><b>Onkure, Inc.<\/b> Employment, Stock Option. <br><b>R. Woessner, <\/b> <br><b>Onkure, Inc.<\/b> Employment, Stock Option. <br><b>J. D. Winkler, <\/b> <br><b>Onkure, Inc.<\/b> Employment, Stock, Stock Option.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10550","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"20","PosterboardNumber":"20","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB174","PresenterBiography":null,"PresenterDisplayName":"Alexander Strait, PhD,BS","PresenterKey":"2d244da5-229e-4e9e-9838-899d8bd0c649","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB174. OKI-219 is an inhibitor of PI3K&#945; H1047R that has brain penetrance and anti-tumor activity in a preclinical intracranial model of metastatic breast cancer","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"600","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"OKI-219 is an inhibitor of PI3K&#945; H1047R that has brain penetrance and anti-tumor activity in a preclinical intracranial model of metastatic breast cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET09-07 PI3K\/AKT inhibitors,,"},{"Key":"Keywords","Value":"PIK3CA,Mutations,Cancer therapy,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. Li<\/b>, L. Fan, C. Liu, Y. Luo, X. Chu, H. Yu, F. Wang, X. Li; <br\/>Hinova Pharmaceuticals, Chengdu Shi, China","CSlideId":"","ControlKey":"9e4530cc-bcf5-4fed-9dc6-56342ba447e9","ControlNumber":"9837","DisclosureBlock":"&nbsp;<b>J. Li, <\/b> None..<br><b>L. Fan, <\/b> None..<br><b>C. Liu, <\/b> None..<br><b>Y. Luo, <\/b> None..<br><b>X. Chu, <\/b> None..<br><b>H. Yu, <\/b> None..<br><b>F. Wang, <\/b> None..<br><b>X. Li, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10551","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"21","PosterboardNumber":"21","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB175","PresenterBiography":null,"PresenterDisplayName":"Jing Li, PhD","PresenterKey":"e92cdb7c-4ffa-4cd4-8f32-1b41801efb92","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB175. Discovery of HP567, a highly potent, brain-penetrating, and H1047R-selective PI3K&#945; inhibitor for the treatment of tumors bearing H1047R mutation","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"600","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discovery of HP567, a highly potent, brain-penetrating, and H1047R-selective PI3K&#945; inhibitor for the treatment of tumors bearing H1047R mutation","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET09-07 PI3K\/AKT inhibitors,,"},{"Key":"Keywords","Value":"Spheroids,Lung cancer: non-small cell,mTOR,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>N. Vella<\/b><sup>1<\/sup>, D. Estêvão<sup>2<\/sup>, T. Cruz<sup>2<\/sup>, M. J. Oliveira<sup>2<\/sup>, A. G. Fenech<sup>1<\/sup>, V. Petroni Magri<sup>1<\/sup>; <br\/><sup>1<\/sup>Department of Clinical Pharmacology and Therapeutics, Faculty of Medicine and Surgery, University of Malta, Msida, Malta, <sup>2<\/sup>i3S – Institute for Research and Innovation in Health, University of Porto, Porto, Portugal","CSlideId":"","ControlKey":"ebb2c27f-ae97-4851-90b4-0686211828e9","ControlNumber":"10624","DisclosureBlock":"&nbsp;<b>N. Vella, <\/b> None..<br><b>D. Estêvão, <\/b> None..<br><b>T. Cruz, <\/b> None..<br><b>M. J. Oliveira, <\/b> None..<br><b>A. G. Fenech, <\/b> None..<br><b>V. Petroni Magri, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10552","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"22","PosterboardNumber":"22","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB176","PresenterBiography":null,"PresenterDisplayName":"Nathan Vella, BS","PresenterKey":"c5756e05-1cf0-4d15-b5d7-a420ddc1e711","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB176. Targeting the PI3K\/Akt\/mTOR pathway in non-small cell lung cancer spheroids","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"600","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Targeting the PI3K\/Akt\/mTOR pathway in non-small cell lung cancer spheroids","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET09-10 Targeted protein degraders,,"},{"Key":"Keywords","Value":"Androgen receptor,Alternative splicing,Proteasome-mediated degradation,Prostate cancer,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. Li<\/b>, Z. Tu, W. Du, X. Xiang, Z. Wen, Y. You, L. Zhao, Y. Chen, C. Yang, H. Yuan, X. Li; <br\/>Hinova Pharmaceuticals, Chengdu Shi, China","CSlideId":"","ControlKey":"da5465f3-d14d-41d1-817e-b3efe9d3c8fb","ControlNumber":"9833","DisclosureBlock":"&nbsp;<b>J. Li, <\/b> None..<br><b>Z. Tu, <\/b> None..<br><b>W. Du, <\/b> None..<br><b>X. Xiang, <\/b> None..<br><b>Z. Wen, <\/b> None..<br><b>Y. You, <\/b> None..<br><b>L. Zhao, <\/b> None..<br><b>Y. Chen, <\/b> None..<br><b>C. Yang, <\/b> None..<br><b>H. Yuan, <\/b> None..<br><b>X. Li, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10553","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"23","PosterboardNumber":"23","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB177","PresenterBiography":null,"PresenterDisplayName":"Jing Li, PhD","PresenterKey":"e92cdb7c-4ffa-4cd4-8f32-1b41801efb92","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB177. Discovery of HC-4955, a novel AR-V7-targeting PROTAC for the treatment of mCRPC","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"600","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discovery of HC-4955, a novel AR-V7-targeting PROTAC for the treatment of mCRPC","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET09-10 Targeted protein degraders,,"},{"Key":"Keywords","Value":"Proteasome-mediated degradation,Triple-negative breast cancer (TNBC),Breast cancer,Androgen receptor,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. Li<\/b>, H. Yuan, K. Chen, Y. Huo, G. Liu, W. Du, X. Li; <br\/>Hinova Pharmaceuticals, Chengdu, China","CSlideId":"","ControlKey":"4d95b331-5b8e-4f56-ba3f-f07f7fc6492f","ControlNumber":"9764","DisclosureBlock":"&nbsp;<b>J. Li, <\/b> None..<br><b>H. Yuan, <\/b> None..<br><b>K. Chen, <\/b> None..<br><b>Y. Huo, <\/b> None..<br><b>G. Liu, <\/b> None..<br><b>W. Du, <\/b> None..<br><b>X. Li, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10554","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"24","PosterboardNumber":"24","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB178","PresenterBiography":null,"PresenterDisplayName":"Jing Li, PhD","PresenterKey":"e92cdb7c-4ffa-4cd4-8f32-1b41801efb92","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB178. HP518, an oral AR-targeting PROTAC for the treatment of AR positive triple negative breast cancer with a novel mechanism of action","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"600","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"HP518, an oral AR-targeting PROTAC for the treatment of AR positive triple negative breast cancer with a novel mechanism of action","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET09-10 Targeted protein degraders,,"},{"Key":"Keywords","Value":"Estrogen receptor,Proteasome-mediated degradation,Breast cancer,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>W. Du<\/b>, Z. Tu, D. Qin, H. Li, J. Duan, S. Liu, M. Zhang, Z. Nie, Z. Yuan, J. Li, X. Li; <br\/>Hinova Pharmaceuticals, Chengdu, China","CSlideId":"","ControlKey":"46846f30-4ac0-47bb-ba13-a7fc78673d8d","ControlNumber":"9836","DisclosureBlock":"&nbsp;<b>W. Du, <\/b> None..<br><b>Z. Tu, <\/b> None..<br><b>D. Qin, <\/b> None..<br><b>H. Li, <\/b> None..<br><b>J. Duan, <\/b> None..<br><b>S. Liu, <\/b> None..<br><b>M. Zhang, <\/b> None..<br><b>Z. Nie, <\/b> None..<br><b>Z. Yuan, <\/b> None..<br><b>J. Li, <\/b> None..<br><b>X. Li, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10555","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"25","PosterboardNumber":"25","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB179","PresenterBiography":null,"PresenterDisplayName":"Wu Du, PhD","PresenterKey":"78991af2-5e97-4254-910c-c966aacdcd0d","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB179. Identification of the highly potent and orally available ER-targeting PROTAC degrader HP568 for the treatment of breast cancer","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"600","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Identification of the highly potent and orally available ER-targeting PROTAC degrader HP568 for the treatment of breast cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET09-11 Topoisomerases,,"},{"Key":"Keywords","Value":"Topoisomerase II inhibitor,Doxorubicin,Annamycin,Cardiotoxicity,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>R. J. Zielinski<\/b><sup>1<\/sup>, K. Grela<sup>1<\/sup>, R. Cardenas-Zuniga<sup>1<\/sup>, S. Skora<sup>1<\/sup>, I. Fokt<sup>1<\/sup>, M. Gagea<sup>1<\/sup>, W. Dempke<sup>2<\/sup>, W. Priebe<sup>1<\/sup>; <br\/><sup>1<\/sup>UT MD Anderson Cancer Center, Houston, TX, <sup>2<\/sup>University Medical School, Munich, Germany","CSlideId":"","ControlKey":"85868264-ea21-4a6a-9a87-3b0dc0a3ea2e","ControlNumber":"10718","DisclosureBlock":"<b>&nbsp;R. J. Zielinski, <\/b> <br><b>Moleculin Biotech<\/b> Stock, Other, Consultant. <br><b>K. Grela, <\/b> <br><b>Moleculin Biotech<\/b> Employment.<br><b>R. Cardenas-Zuniga, <\/b> None..<br><b>S. Skora, <\/b> None.&nbsp;<br><b>I. Fokt, <\/b> <br><b>Moleculin Biotech<\/b> Stock, Stock Option, Other, Consultant.<br><b>M. Gagea, <\/b> None.&nbsp;<br><b>W. Dempke, <\/b> <br><b>Moleculin Biotech<\/b> Employment, Stock, Stock Option. <br><b>W. Priebe, <\/b> <br><b>Moleculin Biotech<\/b> Stock, Stock Option, Grant\/Contract, Patent, Other, Chair of Scientific Board.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10556","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"26","PosterboardNumber":"26","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB180","PresenterBiography":"","PresenterDisplayName":"Rafal Zielinski, PhD","PresenterKey":"7af69dff-da6c-4063-be1e-8ace149e3652","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB180. Non-cardiotoxic properties of annamycin, a clinically evaluated anthracycline and potent topoisomerase 2&#946; poison","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"600","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Non-cardiotoxic properties of annamycin, a clinically evaluated anthracycline and potent topoisomerase 2&#946; poison","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET09-13 Tyrosine kinase and phosphatase inhibitors,,"},{"Key":"Keywords","Value":"ATM,DNA-PK,DNA damage response,Radiosensitization,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Tona M. Gilmer<\/b><sup>1<\/sup>, Chun-Hsiang Lai<sup>2<\/sup>, Kexiao Guo<sup>3<\/sup>, Katherine Deland<sup>2<\/sup>, Kathleen  A.  Ashcraft<sup>4<\/sup>, Amy  E.  Stewart<sup>2<\/sup>, Yaode Wang<sup>5<\/sup>, Jianmin Fu<sup>5<\/sup>, Kris  C.  Wood<sup>2<\/sup>, Deborah  A.  Smith<sup>6<\/sup>, Jonathan  T.  Yang<sup>7<\/sup>, Christopher  T.  Chen<sup>8<\/sup>, Michael  F.  Gensheimer<sup>8<\/sup>, Paul  B.  Romesser<sup>9<\/sup>, Steven  H.  Lin<sup>10<\/sup>, David  G.  Kirsch<sup>11<\/sup>, Michael  B.  Kastan<sup>2<\/sup><br><br\/><sup>1<\/sup>XRad Therapeutics, Orlando, FL,<sup>2<\/sup>Duke University School of Medicine, Durham, NC,<sup>3<\/sup>BioAgilytix Labs, Durham, NC,<sup>4<\/sup>University of North Carolina at Chapel Hill, Chapel Hill, NC,<sup>5<\/sup>Pharmaron, Beijing, China,<sup>6<\/sup>Allucent, Cary, NC,<sup>7<\/sup>University of Washington, Fred Hutchinson Cancer Center, Seattle, WA,<sup>8<\/sup>Stanford University School of Medicine, Palo Alto, CA,<sup>9<\/sup>Memorial Sloan-Kettering Cancer Center, New York, NY,<sup>10<\/sup>MD Anderson Cancer Center, Houston, TX,<sup>11<\/sup>University of Toronto, Princess Margaret Cancer Centre, Toronto, ON, Canada","CSlideId":"","ControlKey":"115953d7-b078-4506-8c9f-86dfcc03f248","ControlNumber":"9768","DisclosureBlock":"<b>&nbsp;T. M. Gilmer, <\/b> <br><b>XRad Therapeutics<\/b> Employment, Stock, Patent, Other, Co-founder. <br><b>Cellarity, Inc<\/b> consultant. <br><b>GSK<\/b> Stock. <br><b>C. Lai, <\/b> <br><b>XRad Therapeutics<\/b> Other, received compensation from research grant to lab. <br><b>K. Guo, <\/b> <br><b>BioAgilytix Labs<\/b> Employment. <br><b>K. Deland, <\/b> <br><b>XRad Therapeutics<\/b> Other, received compensation from research grant to lab.<br><b>K. A. Ashcraft, <\/b> None..<br><b>A. E. Stewart, <\/b> None.&nbsp;<br><b>Y. Wang, <\/b> <br><b>Pharmaron<\/b> Employment. <br><b>XRad Therapeutics<\/b> Patent. <br><b>J. Fu, <\/b> <br><b>Pharmaron<\/b> Employment. <br><b>XRad Therapeutics<\/b> Patent. <br><b>K. C. Wood, <\/b> <br><b>Tarvos Therapeutics<\/b> Stock, Grant\/Contract, Other, Co-founder and consultant. <br><b>Celldom<\/b> Stock, Other, co-founder. <br><b>Element Genomics<\/b> Other, consultant. <br><b>Apple Tree Partners<\/b> Other, consultant. <br><b>Guidepoint Global<\/b> Other, consultant. <br><b>Bantam Pharmaceutical<\/b> Other, consultant. <br><b>G1 Therapeutics.<\/b> Grant\/Contract. <br><b>D. A. Smith, <\/b> <br><b>Allucent<\/b> Independent Contractor. <br><b>J. T. Yang, <\/b> <br><b>Galera Therapeutics<\/b> Independent Contractor. <br><b>Nanocan Therapeutics<\/b> Independent Contractor, Stock. <br><b>Kazia Therapeutics<\/b> Independent Contractor. <br><b>Plus Therapeutics<\/b> Independent Contractor. <br><b>AstraZeneca<\/b> Independent Contractor, Other, research funding. <br><b>XRad Therapeutics<\/b> Other, research funding. <br><b>Debiopharm<\/b> Other, research funding. <br><b>Cantex Therapeutics<\/b> Other, research funding. <br><b>Kazia Therapeutics<\/b> Other, research funding. <br><b>Biocept<\/b> Other, research funding. <br><b>C. T. Chen, <\/b> <br><b>XRad Therapeutics<\/b> Other, research funding. <br><b>Riboscience<\/b> Other, research funding. <br><b>ADC Therapeutics<\/b> Other, research funding. <br><b>ORIC Pharmaceuticals<\/b> Other, research funding. <br><b>Takeda<\/b> Other, research funding. <br><b>Palleon Pharmaceuticals<\/b> Other, research funding. <br><b>Kinnate Biopharma<\/b> Other, research funding. <br><b>Rain Oncology<\/b> Other, research funding. <br><b>Gilead Sciences<\/b> Other, research funding. <br><b>Mersana Therapeutics<\/b> Other, research funding. <br><b>Boxer Capital<\/b> Other, consultant. <br><b>Globepoint Global<\/b> Other, consultant. <br><b>M. F. Gensheimer, <\/b> <br><b>XRad Therapeutics<\/b> Other, research funding. <br><b>Varian Medical Systems<\/b> research funding. <br><b>Roche<\/b> Stock. <br><b>P. B. Romesser, <\/b> <br><b>XRad Therapeutics<\/b> Other, research funding. <br><b>EMD Serono<\/b> Other, consultant. <br><b>Faeth Therapeutics<\/b> Other, consultant. <br><b>Natera<\/b> Other, consultant. <br><b>HPV Cancers Alliance<\/b> Other, medical advisory board. <br><b>Anal Cancer Foundation<\/b> Other, medical advisory board. <br><b>S. H. Lin, <\/b> <br><b>XRad Therapeutics<\/b> Other, consultant. <br><b>Seek Diagnostics<\/b> Stock Option, Other, co-founder. <br><b>Nektar Therapeutics<\/b> Grant\/Contract. <br><b>Beyond Spring Pharmaceuticals<\/b> Grant\/Contract. <br><b>STCube Pharmaceuticals<\/b> Grant\/Contract. <br><b>AstraZeneca<\/b> Other, advisory board. <br><b>Creatv Microtech<\/b> Other, advisory board. <br><b>D. G. Kirsch, <\/b> <br><b>XRad Therapeutics<\/b> Stock, Grant\/Contract, Patent, Other, co-founder. <br><b>Lumicell<\/b> Stock, Other, scientific advisory board. <br><b>Merck<\/b> Other, research funding. <br><b>Bristol Myers Squibb<\/b> Other, research funding. <br><b>Varian Medical Systems<\/b> Other, research funding. <br><b>M. B. Kastan, <\/b> <br><b>XRad Therapeutics<\/b> Stock, Grant\/Contract, Patent, Other, co-founder. <br><b>Dragon Therapeutics<\/b> Other, co-founder.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10557","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"27","PosterboardNumber":"27","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB181","PresenterBiography":null,"PresenterDisplayName":"Tona Gilmer, PhD","PresenterKey":"34951679-96aa-4459-9c8b-7abb4cea140b","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB181. First disclosure of XRD-0394, a novel dual ATM\/DNA-PK inhibitor, that potently radiosensitizes and potentiates PARP and topoisomerase inhibitors","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"600","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"First disclosure of XRD-0394, a novel dual ATM\/DNA-PK inhibitor, that potently radiosensitizes and potentiates PARP and topoisomerase inhibitors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET09-13 Tyrosine kinase and phosphatase inhibitors,,"},{"Key":"Keywords","Value":"ROS1,Resistance,Tyrosine kinase inhibitor,Mutagenesis,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>A. Tangpeerachaikul<\/b>, F. Gu, H. E. Pelish; <br\/>Nuvalent, Cambridge, MA","CSlideId":"","ControlKey":"939d04d1-1e70-4cbd-9568-8c487b489086","ControlNumber":"9900","DisclosureBlock":"<b>&nbsp;A. Tangpeerachaikul, <\/b> <br><b>Nuvalent<\/b> Employment, Stock, Stock Option. <br><b>F. Gu, <\/b> <br><b>Nuvalent<\/b> Employment, Stock, Stock Option. <br><b>H. E. Pelish, <\/b> <br><b>Nuvalent<\/b> Employment, Stock, Stock Option.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10558","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"28","PosterboardNumber":"28","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB182","PresenterBiography":null,"PresenterDisplayName":"Anupong Tangpeerachaikul, BS;PhD","PresenterKey":"8817ee95-f532-4faf-8b15-a5d6e1f02e75","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB182. Mutagenesis screens support potential best-in-class profile for selective, brain-penetrant, and TRK-sparing ROS1 inhibitor zidesamtinib (NVL-520)","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"600","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Mutagenesis screens support potential best-in-class profile for selective, brain-penetrant, and TRK-sparing ROS1 inhibitor zidesamtinib (NVL-520)","Topics":null,"cSlideId":""}]